Received Jul 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | H97H2 | — |
experienced itching and inflammation in the site of administration; experienced itching and inflammation in the site of administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site itching in a female patient who received Herpes zoster (Shingrix) (batch number H97H2, expiry date 28-FEB-2027) for prophylaxis. On 20-MAY-2025, the patient received the 1st dose of Shingrix. On an unknown date, less than a month after receiving Shingrix, the patient experienced injection site itching (Verbatim: experienced itching and inflammation in the site of administration) and injection site inflammation (Verbatim: experienced itching and inflammation in the site of administration). The outcome of the injection site itching and injection site inflammation were unknown. It was unknown if the reporter considered the injection site itching and injection site inflammation to be related to Shingrix. It was unknown if the company considered the injection site itching and injection site inflammation to be related to Shingrix. Additional Information: GSK receipt date: 30-JUN-2025 Other HCP needed guidance after a 56-year-old female patient that received the first dose of Shingrix on 20 May 2025, experienced itching and inflammation in the site of administration of the vaccine for a couple of weeks. She wanted to know how to proceed and if the scheduled second dose could be administered. Also, the health care provider mentioned that the patient received simultaneously the same day another vaccine whose name was not known, and she does not know which vaccine triggered the reaction.